Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2016, Article ID 4370263, 8 pages
http://dx.doi.org/10.1155/2016/4370263
Review Article

From “Kidneys Govern Bones” to Chronic Kidney Disease, Diabetes Mellitus, and Metabolic Bone Disorder: A Crosstalk between Traditional Chinese Medicine and Modern Science

1Department of Chinese Medicine Nephrology, Hubei Provincial Hospital of TCM, Hubei University of Chinese Medicine, Wuhan, Hubei Province, China
2Y. Clare Zhang Practice of Oriental Medicine, Tucson, AZ, USA

Received 15 May 2016; Revised 13 August 2016; Accepted 17 August 2016

Academic Editor: Raffaele Capasso

Copyright © 2016 Xiao-Qin Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Q. Q. Wang, Selected Readings from the Yellow Emperor's Inner Classic, China Press of Traditional Chinese Medicine, Beijing, China, 2nd edition, 2007.
  2. G. Maciocia, The Foundations of Chinese Medicine: A Comprehensive Text for Acupuncturists and Herbalists, Churchill Livingstone, 2nd edition, 2005.
  3. L.-L. Chen, Q. Tang, and J. Yan, “Therapeutic effect of aqueous-extract from a traditional Chinese medical herb Drynaria fortunei on rat experimental model of alveolar bone resorption,” Zhongguo Zhongyao Zazhi, vol. 29, no. 6, pp. 552–553, 2004. View at Google Scholar · View at Scopus
  4. Y.-E. Lee, H.-C. Liu, Y.-L. Lin, S.-H. Liu, R.-S. Yang, and R.-M. Chen, “Drynaria fortunei J. Sm. improves the bone mass of ovariectomized rats through osteocalcin-involved endochondral ossification,” Journal of Ethnopharmacology, vol. 158, pp. 94–101, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. M. A. Abd Jalil, A. N. Shuid, and N. Muhammad, “Role of medicinal plants and natural products on osteoporotic fracture healing,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 714512, 7 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. K.-C. Wong, K.-S. Lee, H.-K. Luk et al., “Er-xian decoction exerts estrogen-like osteoprotective effects in vivo and in vitro,” American Journal of Chinese Medicine, vol. 42, no. 2, pp. 409–426, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. H.-H. Liao, C.-C. Yeh, C.-C. Lin et al., “Prescription patterns of Chinese herbal products for patients with fractures in Taiwan: A Nationwide Population-Based Study,” Journal of Ethnopharmacology, vol. 173, article 9629, pp. 11–19, 2015. View at Publisher · View at Google Scholar · View at Scopus
  8. L. A. Plum and H. F. Deluca, “Vitamin D, disease and therapeutic opportunities,” Nature Reviews Drug Discovery, vol. 9, no. 12, pp. 941–955, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. R. Thadhani, “Is calcitriol life-protective for patients with chronic kidney disease?” Journal of the American Society of Nephrology, vol. 20, no. 11, pp. 2285–2290, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. E. Slatopolsky, C. Weerts, J. Thielan, R. Horst, H. Harter, and K. J. Martin, “Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients,” The Journal of Clinical Investigation, vol. 74, no. 6, pp. 2136–2143, 1984. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Martin, V. David, and L. Darryl Quarles, “Regulation and function of the FGF23/klotho endocrine pathways,” Physiological Reviews, vol. 92, no. 1, pp. 131–155, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Liu, R. Guo, L. G. Simpson, Z.-S. Xiao, C. E. Burnham, and L. D. Quarles, “Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX,” The Journal of Biological Chemistry, vol. 278, no. 39, pp. 37419–37426, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Liu, J. Zhou, W. Tang, X. Jiang, D. W. Rowe, and L. D. Quarles, “Pathogenic role of Fgf23 in Hyp mice,” American Journal of Physiology-Endocrinology and Metabolism, vol. 291, no. 1, pp. E38–E49, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Fukumoto, “Actions and mode of actions of FGF19 subfamily members,” Endocrine Journal, vol. 55, no. 1, pp. 23–31, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Kuro-o, Y. Matsumura, H. Aizawa et al., “Mutation of the mouse klotho gene leads to a syndrome resembling ageing,” Nature, vol. 390, no. 6655, pp. 45–51, 1997. View at Publisher · View at Google Scholar · View at Scopus
  16. H. Kurosu, M. Yamamoto, J. D. Clark et al., “Physiology: suppression of aging in mice by the hormone Klotho,” Science, vol. 309, no. 5742, pp. 1829–1833, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. S.-A. Li, M. Watanabe, H. Yamada, A. Nagai, M. Kinuta, and K. Takei, “Immunohistochemical localization of Klotho protein in brain, kidney, and reproductive organs of mice,” Cell Structure and Function, vol. 29, no. 4, pp. 91–99, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. I. Urakawa, Y. Yamazaki, T. Shimada et al., “Klotho converts canonical FGF receptor into a specific receptor for FGF23,” Nature, vol. 444, no. 7120, pp. 770–774, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. L. D. Quarles, “Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism,” Nature Reviews Endocrinology, vol. 8, no. 5, pp. 276–286, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. M. S. Razzaque and B. Lanske, “Hypervitaminosis D and premature aging: lessons learned from Fgf23 and Klotho mutant mice,” Trends in Molecular Medicine, vol. 12, no. 7, pp. 298–305, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. H. Tsujikawa, Y. Kurotaki, T. Fujimori, K. Fukuda, and Y.-I. Nabeshima, “Klotho, a gene related to a syndrome resembling human premature aging, functions in a negative regulatory circuit of vitamin D endocrine system,” Molecular Endocrinology, vol. 17, no. 12, pp. 2393–2403, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. T. Shimada, M. Kakitani, Y. Yamazaki et al., “Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism,” The Journal of Clinical Investigation, vol. 113, no. 4, pp. 561–568, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. J. R. Stubbs, S. Liu, W. Tang et al., “Role of hyperphosphatemia and 1,25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice,” Journal of the American Society of Nephrology, vol. 18, no. 7, pp. 2116–2124, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Ishii, Y. Yamaguchi, H. Yamamoto, Y. Hanaoka, and Y. Ouchi, “Airspace enlargement with airway cell apoptosis in klotho mice: a model of aging lung,” Journals of Gerontology-Series A Biological Sciences and Medical Sciences, vol. 63, no. 12, pp. 1289–1298, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. T. Nakatani, M. Ohnishi, and M. S. Razzaque, “Inactivation of klotho function induces hyperphosphatemia even in presence of high serum fibroblast growth factor 23 levels in a genetically engineered hypophosphatemic (Hyp) mouse model,” FASEB Journal, vol. 23, no. 11, pp. 3702–3711, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. H. Kawaguchi, N. Manabe, C. Miyaura, H. Chikuda, K. Nakamura, and M. Kuro-o, “Independent impairment of osteoblast and osteoclast differentiation in klotho mouse exhibiting low-turnover osteopenia,” The Journal of Clinical Investigation, vol. 104, no. 3, pp. 229–237, 1999. View at Publisher · View at Google Scholar · View at Scopus
  27. T. Nakatani, B. Sarraj, M. Ohnishi et al., “In vivo genetic evidence for klotho-dependent, fibroblast growth factor 23 (Fgf23) -mediated regulation of systemic phosphate homeostasis,” The FASEB Journal, vol. 23, no. 2, pp. 433–441, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. N. Koh, T. Fujimori, S. Nishiguchi et al., “Severely reduced production of klotho in human chronic renal failure kidney,” Biochemical and Biophysical Research Communications, vol. 280, no. 4, pp. 1015–1020, 2001. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Shardell, R. D. Semba, C. Rosano et al., “Plasma klotho and cognitive decline in older adults: findings from the InCHIANTI Study,” The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, vol. 71, no. 5, pp. 677–682, 2016. View at Publisher · View at Google Scholar
  30. I. Wolf, S. Shahmoon, M. B. Ami et al., “Association between decreased klotho blood levels and organic growth hormone deficiency in children with growth impairment,” PLoS ONE, vol. 9, no. 9, Article ID e107174, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. R. D. Semba, L. Ferrucci, K. Sun et al., “Low plasma klotho concentrations and decline of knee strength in older adults,” The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences, vol. 71, no. 1, pp. 103–108, 2016. View at Publisher · View at Google Scholar
  32. L. Wang and X. Q. Wang, “Research on material foundation of ‘kidney stores essence’ theory based on klotho gene,” Journal of Hubei University of Chinese Medicine, vol. 17, no. 3, pp. 54–56, 2015. View at Google Scholar
  33. K. Lindberg, R. Amin, O. W. Moe et al., “The kidney is the principal organ mediating Klotho effects,” Journal of the American Society of Nephrology, vol. 25, no. 10, pp. 2169–2175, 2014. View at Publisher · View at Google Scholar · View at Scopus
  34. M. C. Hu, M. Shi, J. Zhang et al., “Renal production, uptake, and handling of circulating αKlotho,” Journal of the American Society of Nephrology, vol. 27, no. 1, pp. 79–90, 2015. View at Publisher · View at Google Scholar
  35. M.-C. Hu, M. Shi, J. Zhang, H. Quĩones, M. Kuro-O, and O. W. Moe, “Klotho deficiency is an early biomarker of renal ischemia-reperfusion injury and its replacement is protective,” Kidney International, vol. 78, no. 12, pp. 1240–1251, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. H. Takahashi, H. Komaba, Y. Takahashi et al., “Impact of parathyroidectomy on serum FGF23 and soluble klotho in hemodialysis patients with severe secondary hyperparathyroidism,” Journal of Clinical Endocrinology and Metabolism, vol. 99, no. 4, pp. E652–E658, 2014. View at Publisher · View at Google Scholar · View at Scopus
  37. Y. Shimamura, K. Hamada, K. Inoue et al., “Serum levels of soluble secreted a-Klotho are decreased in the early stages of chronic kidney disease, making it a probable novel biomarker for early diagnosis,” Clinical and Experimental Nephrology, vol. 16, no. 5, pp. 722–729, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. H. Olauson, M. G. Vervloet, M. Cozzolino, Z. A. Massy, P. U. Torres, and T. E. Larsson, “New insights into the FGF23-Klotho axis,” Seminars in Nephrology, vol. 34, no. 6, pp. 586–597, 2014. View at Publisher · View at Google Scholar · View at Scopus
  39. J. Donate-Correa, E. Martin-Nunez, C. Mora-Fernandez, M. Muros-de-Fuentes, N. Perez-Delgado, and J. F. Navarro-Gonzalez, “Klotho in cardiovascular disease: current and future perspectives,” World Journal of Biological Chemistry, vol. 6, no. 4, pp. 351–357, 2015. View at Google Scholar
  40. G. Eknoyan, N. Lameire, R. Barsoum et al., “The burden of kidney disease: improving global outcomes,” Kidney International, vol. 66, no. 4, pp. 1310–1314, 2004. View at Publisher · View at Google Scholar · View at Scopus
  41. S. E. Kahn, M. E. Cooper, and S. Del Prato, “Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future,” The Lancet, vol. 383, no. 9922, pp. 1068–1083, 2014. View at Publisher · View at Google Scholar · View at Scopus
  42. X.-L. Tong, L. Dong, L. Chen, and Z. Zhen, “Treatment of diabetes using traditional Chinese medicine: past, present and future,” The American Journal of Chinese Medicine, vol. 40, no. 5, pp. 877–886, 2012. View at Publisher · View at Google Scholar · View at Scopus
  43. M. Afkarian, M. C. Sachs, B. Kestenbaum et al., “Kidney disease and increased mortality risk in type 2 diabetes,” Journal of the American Society of Nephrology, vol. 24, no. 2, pp. 302–308, 2013. View at Publisher · View at Google Scholar · View at Scopus
  44. A. J. Collins, R. N. Foley, B. Chavers et al., “US renal data system 2013 annual data report,” American Journal of Kidney Diseases, vol. 63, no. 1, supplement, article A7, 2014. View at Publisher · View at Google Scholar
  45. B. Thompson and D. A. Towler, “Arterial calcification and bone physiology: role of the bone-vascular axis,” Nature Reviews Endocrinology, vol. 8, no. 9, pp. 529–543, 2012. View at Publisher · View at Google Scholar · View at Scopus
  46. J. E. Everhart, D. J. Pettitt, W. C. Knowler, F. A. Rose, and P. H. Bennett, “Medial arterial calcification and its association with mortality and complications of diabetes,” Diabetologia, vol. 31, no. 1, pp. 16–23, 1988. View at Publisher · View at Google Scholar · View at Scopus
  47. S. Lehto, L. Niskanen, M. Suhonen, T. Rönnemaa, and M. Laakso, “Medial artery calcification: a neglected harbinger of cardiovascular complications in non-insulin-dependent diabetes mellitus,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 16, no. 8, pp. 978–983, 1996. View at Publisher · View at Google Scholar · View at Scopus
  48. A. P. Sage, Y. Tintut, and L. L. Demer, “Regulatory mechanisms in vascular calcification,” Nature Reviews Cardiology, vol. 7, no. 9, pp. 528–536, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. M. Wan, C. Smith, V. Shah et al., “Fibroblast growth factor 23 and soluble klotho in children with chronic kidney disease,” Nephrology Dialysis Transplantation, vol. 28, no. 1, pp. 153–161, 2013. View at Publisher · View at Google Scholar · View at Scopus
  50. I. Pavik, P. Jaeger, L. Ebner et al., “Secreted Klotho and FGF23 in chronic kidney disease stage 1 to 5: a sequence suggested from a cross-sectional study,” Nephrology Dialysis Transplantation, vol. 28, no. 2, pp. 352–359, 2013. View at Publisher · View at Google Scholar · View at Scopus
  51. H. R. Kim, B. Y. Nam, D. W. Kim et al., “Circulating α-klotho levels in CKD and relationship to progression,” American Journal of Kidney Diseases, vol. 61, no. 6, pp. 899–909, 2013. View at Publisher · View at Google Scholar · View at Scopus
  52. E. Y. Lee, S. S. Kim, J.-S. Lee et al., “Soluble α-klotho as a novel biomarker in the early stage of nephropathy in patients with type 2 diabetes,” PLoS ONE, vol. 9, no. 8, article e102984, 2014. View at Publisher · View at Google Scholar · View at Scopus
  53. C. Wu, Q. Wang, C. Lv et al., “The changes of serum sKlotho and NGAL levels and their correlation in type 2 diabetes mellitus patients with different stages of urinary albumin,” Diabetes Research and Clinical Practice, vol. 106, no. 2, pp. 343–350, 2014. View at Publisher · View at Google Scholar · View at Scopus
  54. P. Evenepoel, M. Rodriguez, and M. Ketteler, “Laboratory abnormalities in CKD-MBD: markers, predictors, or mediators of disease?” Seminars in Nephrology, vol. 34, no. 2, pp. 151–163, 2014. View at Publisher · View at Google Scholar · View at Scopus
  55. J. F. Navarro-González, J. Donate-Correa, M. M. De Fuentes, H. Pérez-Hernández, R. Martínez-Sanz, and C. Mora-FernáNdez, “Reduced Klotho is associated with the presence and severity of coronary artery disease,” Heart, vol. 100, no. 1, pp. 34–40, 2014. View at Publisher · View at Google Scholar · View at Scopus
  56. J. Donate-Correa, E. Martín-Núñez, R. Martínez-Sanz et al., “Influence of Klotho gene polymorphisms on vascular gene expression and its relationship to cardiovascular disease,” Journal of Cellular and Molecular Medicine, vol. 20, no. 1, pp. 128–133, 2016. View at Publisher · View at Google Scholar · View at Scopus
  57. E. J. Rhee, K. W. Oh, E. J. Yun et al., “Relationship between polymorphisms G395A in promoter and C1818T in exon 4 of the KLOTHO gene with glucose metabolism and cardiovascular risk factors in Korean women,” Journal of Endocrinological Investigation, vol. 29, no. 7, pp. 613–618, 2006. View at Publisher · View at Google Scholar · View at Scopus
  58. Y. Kim, S. J. Jeong, H. S. Lee et al., “Polymorphism in the promoter region of the klotho gene (G-395A) is associated with early dysfunction in vascular access in hemodialysis patients,” Korean Journal of Internal Medicine, vol. 23, no. 4, pp. 201–207, 2008. View at Publisher · View at Google Scholar · View at Scopus
  59. O. Asai, K. Nakatani, T. Tanaka et al., “Decreased renal α-Klotho expression in early diabetic nephropathy in humans and mice and its possible role in urinary calcium excretion,” Kidney International, vol. 81, no. 6, pp. 539–547, 2012. View at Publisher · View at Google Scholar · View at Scopus
  60. H. Mitani, N. Ishizaka, T. Aizawa et al., “In vivo klotho gene transfer ameliorates angiotensin II-induced renal damage,” Hypertension, vol. 39, no. 4, pp. 838–843, 2002. View at Publisher · View at Google Scholar · View at Scopus
  61. Y. Lin and Z. Sun, “Antiaging gene klotho attenuates pancreatic β-cell apoptosis in type 1 diabetes,” Diabetes, vol. 64, no. 12, pp. 4298–4311, 2015. View at Publisher · View at Google Scholar
  62. Y. Lin and Z. Sun, “In vivo pancreatic β-cell-specific expression of antiaging gene Klotho: a novel approach for preserving β-cells in type 2 diabetes,” Diabetes, vol. 64, no. 4, pp. 1444–1458, 2015. View at Publisher · View at Google Scholar
  63. M. Deng, Y. Luo, Y. Li et al., “Klotho gene delivery ameliorates renal hypertrophy and fibrosis in streptozotocin-induced diabetic rats by suppressing the Rho-associated coiled-coil kinase signaling pathway,” Molecular Medicine Reports, vol. 12, no. 1, pp. 45–54, 2015. View at Publisher · View at Google Scholar · View at Scopus
  64. P.-C. Hsu, Y.-T. Tsai, J.-N. Lai, C.-T. Wu, S.-K. Lin, and C.-Y. Huang, “Integrating traditional Chinese medicine healthcare into diabetes care by reducing the risk of developing kidney failure among type 2 diabetic patients: a population-based case control study,” Journal of Ethnopharmacology, vol. 156, pp. 358–364, 2014. View at Publisher · View at Google Scholar
  65. C.-Y. Huang, Y.-T. Tsai, J.-N. Lai, and F.-L. Hsu, “Prescription pattern of Chinese herbal products for diabetes mellitus in Taiwan: a population-based study,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 201329, 10 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  66. F. Lian, G. Li, X. Chen et al., “Chinese herbal medicine tianqi reduces progression from impaired glucose tolerance to diabetes: a double-blind, randomized, placebo-controlled, multicenter trial,” Journal of Clinical Endocrinology and Metabolism, vol. 99, no. 2, pp. 648–655, 2014. View at Publisher · View at Google Scholar · View at Scopus
  67. Z. D. Shao, X. Q. Wang, Y. Li, and L. Y. Wu, “Clinical study on chronic renal failure treated with Shen'An pills,” Journal of Traditional Chinese Medicine, vol. 44, no. 3, pp. 194–196, 2003. View at Google Scholar
  68. Z. D. Shao, X. Q. Wang, and Y. M. Ba, The Foundations of Chinese Medicine Nephrology, Wuhan University Press, 2005.
  69. W. W. He, H. G. Feng, Q. Wang, X. Q. Wang, and S. Ba, “Study of semi-bionic extraction process of Herba Epimedii and Astragalus Membranaceus in Shen-An extracts,” Herald of Medicine, vol. 29, no. 8, pp. 1060–1062, 2010. View at Google Scholar
  70. C. Li, Q. Li, Q. Mei, and T. Lu, “Pharmacological effects and pharmacokinetic properties of icariin, the major bioactive component in Herba Epimedii,” Life Sciences, vol. 126, pp. 57–68, 2015. View at Publisher · View at Google Scholar · View at Scopus
  71. M.-Y. Qi, Kai-Chen, H.-R. Liu, Y.-H. Su, and S.-Q. Yu, “Protective effect of Icariin on the early stage of experimental diabetic nephropathy induced by streptozotocin via modulating transforming growth factor β1 and type IV collagen expression in rats,” Journal of Ethnopharmacology, vol. 138, no. 3, pp. 731–736, 2011. View at Publisher · View at Google Scholar · View at Scopus
  72. Y.-C. Li, X.-S. Ding, H.-M. Li, and C. Zhang, “Icariin attenuates high glucose-induced type IV collagen and fibronectin accumulation in glomerular mesangial cells by inhibiting transforming growth factor-β production and signalling through G protein-coupled oestrogen receptor 1,” Clinical and Experimental Pharmacology and Physiology, vol. 40, no. 9, pp. 635–643, 2013. View at Publisher · View at Google Scholar · View at Scopus
  73. J. Fu, Z. Wang, L. Huang et al., “Review of the botanical characteristics, phytochemistry, and pharmacology of Astragalus membranaceus (Huangqi),” Phytotherapy Research, vol. 28, no. 9, pp. 1275–1283, 2014. View at Publisher · View at Google Scholar · View at Scopus
  74. J. Zhang, X. Xie, C. Li, and P. Fu, “Systematic review of the renal protective effect of Astragalus membranaceus (root) on diabetic nephropathy in animal models,” Journal of Ethnopharmacology, vol. 126, no. 2, pp. 189–196, 2009. View at Publisher · View at Google Scholar · View at Scopus
  75. Y. Wang, C. Lin, Q. Ren, Y. Liu, and X. Yang, “Astragaloside effect on TGF-β1, SMAD2/3, and α-SMA expression in the kidney tissues of diabetic KKAy mice,” International Journal of Clinical and Experimental Pathology, vol. 8, no. 6, pp. 6828–6834, 2015. View at Google Scholar · View at Scopus
  76. Z. Lu, Y. Zeng, F. Lu, X. Liu, and C. Zou, “Rhubarb enema attenuates renal tubulointerstitial fibrosis in 5/6 nephrectomized rats by alleviating indoxyl sulfate overload,” PLoS ONE, vol. 10, no. 12, Article ID e0144726, 2015. View at Publisher · View at Google Scholar · View at Scopus
  77. G. Zhang and A. M. El Nahas, “The effect of rhubarb extract on experimental renal fibrosis,” Nephrology Dialysis Transplantation, vol. 11, no. 1, pp. 186–190, 1996. View at Publisher · View at Google Scholar · View at Scopus
  78. X. Q. Wang, S. W. Xiang, and Q. Tang, “Shen'An extract inhibits the expression of AP-1 and TGF-β1 in renal tissues of diabetic nephrophy mice,” Chinese Journal of Integrated Traditional and Western Nephrology, vol. 11, no. 12, pp. 1057–1061, 2010. View at Google Scholar
  79. X. Q. Wang, Q. Tang, J. Ma, and S. W. Xiang, “Effect of Shen'An extract on expression of renal AGE and RAGEs in diabetic nephropathy mice,” Journal of Hubei University of Chinese Medicine, vol. 12, no. 5, pp. 3–6, 2010. View at Google Scholar
  80. X. R. Zou, X. Q. Wang, X. H. Ma, S. Z. Zhu, and H. L. Zhou, “Effect of Shen'An granule on the expression of FGF-23 and bone metabolism of renal osteodystrophy model rat osseous tissue,” Journal of Clinical Nephrology, vol. 12, no. 9, pp. 418–421, 2012. View at Google Scholar
  81. X. R. Zou, X. Q. Wang, and C. J. Wang, “Research on klotho gene expression in the remnant kidney of model rats and the intervention effects of epimedium-astragalus-rhubarb compound,” Military Medical Journal of South China, vol. 29, no. 3, pp. 37–41, 2015. View at Google Scholar